11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
310 651 8041
https://www.immixbio.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 14
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, CEO & Chairman | 669k | N/D | 1973 |
Mr. Gabriel Morris B.A. | CFO & Director | 669k | N/D | 1987 |
Mr. Nandan Oza B.S. | Head of Chemistry, Manufacturing & Control | N/D | N/D | 1962 |
Dr. David Marks | Chief Medical Officer of Cell Therapy | N/D | N/D | N/D |
Mr. Gerhard Bauer | Head of Cell Thearpy Manufacturing | N/D | N/D | N/D |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
L'ISS Governance QualityScore di Immix Biopharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.